These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

619 related items for PubMed ID: 27008031

  • 1. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O.
    Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
    [Abstract] [Full Text] [Related]

  • 2. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V, Bramanti P, Mazzon E.
    Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
    [Abstract] [Full Text] [Related]

  • 3. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [Abstract] [Full Text] [Related]

  • 4. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 5. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P, Hagman S, Kolasa M, Koivisto K, Verkkoniemi-Ahola A, Airas L, Elovaara I.
    Mult Scler Relat Disord; 2015 Jul 17; 4(4):334-8. PubMed ID: 26195052
    [Abstract] [Full Text] [Related]

  • 6. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.
    Clin Ther; 2016 Mar 17; 38(3):670-5. PubMed ID: 26856928
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.
    Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L.
    Expert Opin Drug Saf; 2017 Aug 17; 16(8):963-972. PubMed ID: 28641055
    [Abstract] [Full Text] [Related]

  • 8. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K, Collin F, Tarasiuk J, Czarnowska A, Chorąży M, Mirończuk A, Kochanowicz J, Kułakowska A.
    Eur Neurol; 2020 Aug 17; 83(5):487-492. PubMed ID: 33027785
    [Abstract] [Full Text] [Related]

  • 9. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
    Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D.
    Curr Med Res Opin; 2014 Apr 17; 30(4):629-35. PubMed ID: 24289170
    [Abstract] [Full Text] [Related]

  • 10. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr 17; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 11. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Apr 17; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 12. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J.
    Eur J Neurol; 2016 Jun 17; 23(6):1079-85. PubMed ID: 27018481
    [Abstract] [Full Text] [Related]

  • 13. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K, Gold R.
    J Neurol; 2011 Nov 17; 258(11):1920-8. PubMed ID: 21647730
    [Abstract] [Full Text] [Related]

  • 14. Spanish consensus on the use of natalizumab (Tysabri®)-2013.
    Fernández O, García-Merino JA, Arroyo R, Álvarez-Cermeño JC, Izquierdo G, Saiz A, Olascoaga J, Rodríguez-Antigüedad A, Prieto JM, Oreja-Guevara C, Hernández MA, Moral E, Meca J, Montalbán X.
    Neurologia; 2015 Jun 17; 30(5):302-14. PubMed ID: 24360652
    [Abstract] [Full Text] [Related]

  • 15. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P, Virtanen E, Elovaara I, Hagman S, Auvinen E.
    J Neurovirol; 2017 Oct 17; 23(5):734-741. PubMed ID: 28831768
    [Abstract] [Full Text] [Related]

  • 16. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
    Zingaropoli MA, Iannetta M, Pontecorvo S, Anzivino E, Prezioso C, Rodio DM, Morreale M, D'Abramo A, Oliva A, Lichtner M, Cortese A, Frontoni M, Pietropaolo V, Francia A, Mastroianni CM, Vullo V, Ciardi MR.
    Biomed Res Int; 2018 Oct 17; 2018():5297980. PubMed ID: 29682547
    [Abstract] [Full Text] [Related]

  • 17. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population.
    Correia I, Jesus-Ribeiro J, Batista S, Martins AI, Nunes C, Macário MC, Cunha L, Sousa L.
    J Clin Neurosci; 2017 Nov 17; 45():257-260. PubMed ID: 28844615
    [Abstract] [Full Text] [Related]

  • 18. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.
    BMC Neurol; 2016 Jul 12; 16():98. PubMed ID: 27405225
    [Abstract] [Full Text] [Related]

  • 19. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
    Kinner M, Prehn C, Schneider R, Schroeder C, Kolb E, Gold R, Hoepner R, Chan A.
    Eur J Neurol; 2021 Mar 12; 28(3):921-927. PubMed ID: 33085811
    [Abstract] [Full Text] [Related]

  • 20. Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis.
    Rodríguez de Castro B, Barbosa CM, Ayastuy Ruiz A, Fernández González B.
    Eur J Hosp Pharm; 2021 Mar 12; 28(2):112-114. PubMed ID: 33608441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.